1. Cutaneous adverse reactions following SARS‐CoV‐2 vaccine booster dose: a real‐life multicentre experience. (10th July 2022) Authors: Avallone, G.; Cavallo, F.; Astrua, C.; Caldarola, G.; Conforti, C.; De Simone, C.; di Meo, N.; di Stefani, A.; Genovese, G.; Maronese, C.A.; Marzano, A.V.; Parente, R.; Quaglino, P.; Roccuzzo, G.; Tassone, F.; Zalaudek, I.; Senetta, R.; Ribero, S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 11(2022) Page Start: e876 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks. (26th July 2022) Authors: Mastorino, L.; Cantafio Duò, V.L.; Vecco, C.; Gelato, F.; Giordano, S.; Roccuzzo, G.; Cavaliere, G.; Avallone, G.; Ortoncelli, M.; Ribero, S.; Quaglino, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 12(2022) Page Start: e1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Real‐life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. (24th March 2022) Authors: Avallone, G.; Cariti, C.; Dapavo, P.; Ortoncelli, M.; Conforto, L.; Mastorino, L.; Roccuzzo, G.; Cavallo, F.; Rubatto, M.; Quaglino, P.; Ribero, S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 7(2022) Page Start: e574 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗